Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Aug 2017 Status changed from not yet recruiting to recruiting.
- 13 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.